Lithium toxicity occurs when serum concentrations reach ≥1.5 mEq/L, dangerously close to the therapeutic range of 0.8–1.2 mEq/L. [1-2] The narrow therapeutic index makes this one of the most clinically important drug toxicities encountered in emergency and primary care settings. Three patterns are recognized: acute (overdose in lithium-naïve patient), acute-on-chronic (overdose in patient on lithium therapy), and chronic (gradual accumulation from impaired elimination) — with chronic being the most common and most dangerous pattern. [3-4]
1. History
- Determine the pattern of toxicity: intentional overdose vs. unintentional chronic accumulation vs. acute-on-chronic
- Timing and amount of ingestion (if acute); time of last dose; formulation (immediate-release vs. extended-release)
- Recent changes in dose, medication additions, or discontinuations
- Symptoms: nausea, vomiting, diarrhea, tremor, confusion, ataxia, slurred speech, muscle twitching
- Precipitating factors: recent illness with fever, vomiting/diarrhea, decreased oral intake, dehydration, new medications (NSAIDs, diuretics, ACE inhibitors)
- Polyuria/polydipsia suggesting lithium-induced nephrogenic diabetes insipidus (which itself predisposes to dehydration and toxicity) [1]
- Important negatives: seizure, syncope, chest pain, suicidal intent
2. Alarm Features
- Seizures, coma, or altered level of consciousness — risk of irreversible brain damage at levels >3 mEq/L [1]
- Coarse tremor progressing to clonus or myoclonus
- Cardiovascular collapse or life-threatening dysrhythmias
- Oliguria/anuria suggesting renal failure
- Aspiration risk in obtunded patients
- Fever with concurrent lithium use — strongly associated with development of SILENT (Syndrome of Irreversible Lithium-Effectuated Neurotoxicity), with fever/infection reported in ~48% of SILENT cases [5]
3. Medications
Medications that increase lithium levels (reduce renal clearance): [1][6]
- NSAIDs (ibuprofen, naproxen, indomethacin) — decrease renal blood flow
- Diuretics (thiazides > loop) — sodium depletion reduces lithium clearance
- ACE inhibitors / ARBs (lisinopril, enalapril, losartan)
- Metronidazole — reduced renal clearance
- Calcium channel blockers — increased neurotoxicity risk
Medications that decrease lithium levels: [7]
- Acetazolamide, theophylline, sodium bicarbonate, urea — increase urinary lithium excretion
- SGLT2 inhibitors — may decrease serum lithium concentrations [7]
Other important interactions:
- Serotonergic drugs (SSRIs, SNRIs, MAOIs) — risk of serotonin syndrome [1]
- Antipsychotics — risk of encephalopathic syndrome and neuroleptic malignant syndrome [1][8]
- Neuromuscular blocking agents — lithium may prolong paralysis [2]
Contraindicated in management: Activated charcoal does NOT adsorb lithium [1-2]
4. Diet
- Sodium intake is critical: low-sodium diets reduce lithium clearance and precipitate toxicity [1]
- Dehydration from any cause (vomiting, diarrhea, poor oral intake, excessive sweating) increases toxicity risk
- Patients should maintain consistent sodium and fluid intake
- Caffeine (xanthine) may increase lithium excretion; abrupt cessation could raise levels
5. Review of Systems
- Neuro: tremor (fine → coarse), confusion, ataxia, slurred speech, visual changes, weakness, muscle twitching, seizures
- GI: nausea, vomiting, diarrhea, bloating (often earliest symptoms)
- Cardiac: palpitations, presyncope
- Renal: polyuria, polydipsia (nephrogenic DI)
- Respiratory: dyspnea
- Endocrine: symptoms of hypothyroidism (fatigue, weight gain, cold intolerance)
6. Collateral History and Family History
- Confirm psychiatric diagnosis (bipolar disorder) and current medication regimen
- Verify adherence pattern — recent dose changes, missed doses followed by "catch-up" dosing
- Assess for intentional overdose vs. accidental — determine suicidal ideation
- Pharmacy records for recent prescription fills and interacting medications
- Family/caregiver input on baseline mental status and recent behavioral changes
- Access to medications in the home
7. Risk Factors
- Impaired renal function — the single most important risk factor [1][4]
- Volume depletion/dehydration from any cause [1]
- Febrile illness — both reduces clearance and independently increases risk of SILENT [5]
- Elderly age (reduced GFR, polypharmacy) [1]
- Concomitant interacting medications (NSAIDs, diuretics, ACEi/ARBs) [6]
- Changes in electrolyte concentrations, especially sodium and potassium [1]
- Significant cardiovascular disease [1]
- Chronic lithium use (tissue stores accumulate)
- Extended-release formulations (delayed and prolonged absorption)
8. Differential Diagnosis
- Serotonin syndrome — especially if co-administered with serotonergic agents; look for clonus, hyperthermia, agitation
- Neuroleptic malignant syndrome — rigidity, hyperthermia, autonomic instability; can co-occur with lithium toxicity [8]
- Other toxic ingestions — co-ingestants in intentional overdose (benzodiazepines, antipsychotics, anticonvulsants)
- Metabolic encephalopathy — hyponatremia, hypercalcemia, uremia, hepatic encephalopathy
- CNS infection — meningitis/encephalitis (especially if febrile)
- Stroke/intracranial pathology — if focal neurological deficits present
- Thyroid storm or myxedema coma — lithium affects thyroid function
- Nephrogenic diabetes insipidus — from lithium itself, causing hypernatremia
9. Past Medical History
- Bipolar disorder — duration, stability, prior episodes of toxicity
- Chronic kidney disease — baseline GFR is essential; lithium itself causes progressive renal decline [9]
- Prior lithium-induced nephrogenic DI
- Thyroid disease (lithium-induced hypothyroidism)
- Hyperparathyroidism/hypercalcemia (lithium-associated) [1]
- Cardiac history — prior arrhythmias, heart failure
- Previous suicide attempts or psychiatric hospitalizations
10. Physical Exam
- Vitals: Bradycardia (lithium can cause sinus node dysfunction), hypotension in severe cases; check temperature (fever worsens prognosis) [10]
- Neuro (most important system):
- Mild: fine tremor, hyperreflexia
- Moderate: coarse tremor, ataxia, nystagmus, slurred speech, hyperreflexia, muscle fasciculations
- Severe: clonus, rigidity, obtundation, seizures, coma [1][6]
- GI: abdominal tenderness, hyperactive bowel sounds (early)
- Volume status: mucous membranes, skin turgor, capillary refill
- Thyroid: goiter (chronic use)
- Assess for signs of co-ingestion or NMS (rigidity, hyperthermia, diaphoresis)
11. Lab Studies
- Serum lithium level — the cornerstone; repeat q2–4h in acute ingestions as levels may continue to rise (especially with extended-release formulations) [1]
- Therapeutic: 0.6–1.2 mEq/L
- Toxic: ≥1.5 mEq/L
- Severe/life-threatening: >3.0 mEq/L [1]
- Note: In chronic toxicity, clinical severity correlates poorly with serum levels — patients may be severely toxic at lower levels [3]
- BMP/CMP: Na, K, BUN, creatinine, glucose, calcium — assess renal function, electrolytes, dehydration
- TSH — lithium-induced hypothyroidism
- Urinalysis with specific gravity — assess concentrating ability (nephrogenic DI)
- CBC — leukocytosis (lithium causes benign leukocytosis at therapeutic levels)
- Serum osmolality and urine osmolality — if DI suspected
- Acetaminophen and salicylate levels — rule out co-ingestion in intentional overdose
- Pregnancy test in women of childbearing age (lithium is teratogenic — Ebstein anomaly) [11]
12. Imaging
- Not routinely required in straightforward lithium toxicity
- CT head — if altered mental status with concern for intracranial pathology or if focal neurological deficits
- Chest X-ray — if aspiration suspected (obtunded patients) [12]
- MRI brain — in cases of persistent neurological deficits (SILENT); may show cerebellar atrophy and gliosis [5][13]
- Abdominal X-ray/KUB — lithium tablets may be radiopaque; can help assess pill burden in large acute ingestions and guide whole bowel irrigation
13. Special Tests
- Whole bowel irrigation (WBI) — consider for large acute ingestions, especially sustained-release formulations; PEG solution at 1,500–2,000 mL/hr in adults until rectal effluent is clear. Recent data suggest WBI reduces lithium burden even when administered >4 hours post-ingestion [14-16]
- Serial lithium levels — essential to track trajectory; rebound after hemodialysis is common due to redistribution from tissues [1][3]
- Poison Control consultation (1-800-222-1222) [1]
- Toxicology consultation — recommended for all moderate-to-severe cases
14. ECG
An ECG should be obtained in all patients presenting with lithium toxicity. [17]
Key findings:
- T-wave flattening or inversion — most common ECG change [18]
- QTc prolongation — present in ~24% of intoxication episodes; QTc >500 ms in 54% of those with prolongation [17]
- ST-segment changes [1]
- Sinus bradycardia and sinus node dysfunction [10]
- AV block (first-degree or higher) [10]
- Premature ventricular beats [10]
- Rare: myocarditis pattern
Pearl: Cardiac effects are generally concentration-dependent and reversible with declining levels, but QTc >500 ms carries risk of torsades de pointes. [17]
15. Assessment
Severity stratification: [1][4][6]
Critical caveats:
- Chronic toxicity produces more severe symptoms at lower serum levels than acute toxicity because tissue (especially CNS) stores are already saturated [3-4]
- Lithium takes up to 24 hours to distribute into brain tissue, so acute toxicity symptoms may be delayed [1]
- SILENT (Syndrome of Irreversible Lithium-Effectuated Neurotoxicity) — persistent cerebellar dysfunction (ataxia, nystagmus, dysarthria, cognitive impairment) lasting >2 months post-exposure; cerebellar sequelae in ~79% of cases; may occur even at levels <2.5 mEq/L [3][5][13]
16. Treatment Plan
Initial stabilization
- ABCs — protect airway in obtunded patients
- Discontinue lithium immediately
- Discontinue all interacting medications (NSAIDs, diuretics, ACEi/ARBs)
- IV access, cardiac monitoring, continuous pulse oximetry
Volume resuscitation
- IV normal saline — aggressive hydration to restore volume and enhance renal lithium clearance; monitor for hypernatremia [1]
- Correct electrolyte abnormalities
GI decontamination (acute ingestions)
- Activated charcoal is NOT effective — lithium is not adsorbed [1-2]
- Whole bowel irrigation — consider for large acute ingestions (especially sustained-release); administer PEG at 1.5–2 L/hr in adults [14-16]
- Gastric lavage may be considered if very early presentation [1]
Hemodialysis — the definitive treatment for severe toxicity. Per the EXTRIP Workgroup recommendations: [19]
- Recommended if:
- Renal impairment AND lithium >4.0 mEq/L
- Decreased level of consciousness, seizures, or life-threatening dysrhythmias (regardless of level)
- Suggested if:
- Lithium >5.0 mEq/L
- Significant confusion
- Expected time to reduce lithium <1.0 mEq/L exceeds 36 hours
- Continue HD until clinical improvement or lithium <1.0 mEq/L (minimum 6 hours if level not readily available) [19]
- Hemodialysis is preferred; continuous renal replacement therapy (CRRT) is an acceptable alternative [19]
- Monitor for post-dialysis rebound — lithium redistributes from tissues; repeat levels 6–8 hours after HD and consider repeat sessions [1][3]
For chronic toxicity with lower levels (≥2.0 mEq/L): HD thresholds are lower, especially with altered mental status or renal insufficiency [3]
Seizure management: Benzodiazepines first-line
17. Disposition
Admit (ICU)
- Severe neurological symptoms (seizures, coma, significant AMS)
- Lithium level >2.5 mEq/L with symptoms
- Requiring hemodialysis
- Hemodynamic instability
- Aspiration or respiratory compromise
Admit (monitored bed)
- Moderate symptoms (ataxia, confusion, coarse tremor)
- Rising lithium levels on serial monitoring
- Renal insufficiency with elevated levels
- Acute ingestion of large or sustained-release formulation (levels may continue to rise)
Observation
- Mild symptoms with lithium 1.5–2.0 mEq/L and normal renal function
- Serial levels trending down
- Adequate volume resuscitation
Discharge criteria
- Asymptomatic with lithium level <1.5 mEq/L and trending down on serial measurements
- Normal renal function
- Adequate oral intake
- Psychiatric clearance if intentional ingestion
Consult triggers
- Nephrology — for hemodialysis
- Toxicology/Poison Control — all moderate-to-severe cases
- Psychiatry — all intentional ingestions; medication management planning
18. Follow Up / Return Precautions
- Follow-up within 48–72 hours with prescribing psychiatrist for medication reassessment
- Recheck lithium level and renal function at follow-up
- If lithium is to be restarted, do so cautiously — tissue stores may release lithium, and levels should be monitored closely [1]
Return precautions — seek immediate care for
- Recurrence of tremor, confusion, unsteady gait, slurred speech
- Persistent vomiting or diarrhea preventing hydration
- Decreased urine output
- Seizure or loss of consciousness
- Fever while on lithium
Patient counseling
- Maintain consistent sodium and fluid intake
- Avoid NSAIDs (use acetaminophen for pain)
- Seek medical attention during any illness causing dehydration (vomiting, diarrhea, fever)
- Inform all providers about lithium use before starting new medications
- Never double doses if a dose is missed
- Expected recovery: mild toxicity typically resolves within 1–3 days; severe cases may have prolonged recovery or permanent neurological sequelae (SILENT) [3][13]
References
1. FDA Drug Label. — Updated date: 2023-10-02. Food and Drug Administration.
2. FDA Drug Label. — Updated date: 2025-08-20. Food and Drug Administration.
3. Hemodialysis for Lithium Poisoning. — Lavonas EJ, Buchanan J. The Cochrane Database of Systematic Reviews. 2015.
4. Lithium Poisoning. — Baird-Gunning J, Lea-Henry T, Hoegberg LCG, Gosselin S, Roberts DM. Journal of Intensive Care Medicine. 2017.
5. A Reappraisal of the Role of Fever in the Occurrence of Neurological Sequelae Following Lithium Intoxication: A Systematic Review. — Verdoux H, Debruyne AL, Queuille E, De Leon J. Expert Opinion on Drug Safety. 2021.
6. FDA Drug Label. — Updated date: 2022-11-22. Food and Drug Administration.
7. FDA Drug Label. — Updated date: 2023-06-28. Food and Drug Administration.
8. Subcortical Structure Disruption in Diffusion Tensor Tractography of the Patient With the Syndrome of Irreversible Lithium-Effectuated Neurotoxicity Combined With Neuroleptic Malignant Syndrome: A Case Report. — Rhee SY, Kim HS. Clinical Neuropharmacology. 2021.
9. Diagnosis and Treatment of Bipolar Disorder: A Review. — Nierenberg AA, Agustini B, Köhler-Forsberg O, et al. The Journal of the American Medical Association. 2023.
10. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association. — Page RL, O'Bryant CL, Cheng D, et al. Circulation. 2016.
11. Lithium for Acute Mania. — McKnight RF, de La Motte de Broöns de Vauvert SJGN, Chesney E, et al. The Cochrane Database of Systematic Reviews. 2019.
12. FDA Drug Label. — Updated date: 2025-09-04. Food and Drug Administration.
13. Syndrome of Irreversible Lithium-Effectuated Neurotoxicity (SILENT): A Preventable Cerebellar Disorder. — Marmol S, Beltre N, Margolesky J. Cerebellum. 2024.
14. Acute Medication Poisoning. — Vega IL, Griswold MK, Laskey D. American Family Physician. 2024.
15. Position Paper Update: Whole Bowel Irrigation for Gastrointestinal Decontamination of Overdose Patients. — Thanacoody R, Caravati EM, Troutman B, et al. Clinical Toxicology. 2015.
16. The Effect of Decontamination and Elimination in Large Acute Lithium Overdoses. — Berling I, Isbister GK. Clinical Toxicology. 2026.
17. Effects of Toxic Lithium Levels on ECG-Findings From the LiSIE Retrospective Cohort Study. — Truedson P, Ott M, Lindmark K, et al. Journal of Clinical Medicine. 2022.
18. The Cardiovascular Effects of Lithium in Man. A Review of the Literature. — Tilkian AG, Schroeder JS, Kao JJ, Hultgren HN. The American Journal of Medicine. 1976.
19. Extracorporeal Treatment for Lithium Poisoning: Systematic Review and Recommendations From the EXTRIP Workgroup. — Decker BS, Goldfarb DS, Dargan PI, et al. Clinical Journal of the American Society of Nephrology : CJASN. 2015.